$415 Million is the total value of FRAZIER MANAGEMENT LLC's 17 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ANAB | ANAPTYSBIO INC | $169,216,000 | +14.5% | 2,316,447 | 0.0% | 40.73% | +6.8% | |
| KRYS | KRYSTAL BIOTECH INC | $28,788,000 | +58.3% | 875,000 | 0.0% | 6.93% | +47.7% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $28,574,000 | -11.8% | 1,887,332 | 0.0% | 6.88% | -17.7% | |
| GRTS | GRITSTONE ONCOLOGY INC | $27,421,000 | -13.9% | 2,061,758 | 0.0% | 6.60% | -19.7% | |
| ALNA | ALLENA PHARMACEUTICALS INC | $23,379,000 | +28.8% | 3,330,373 | 0.0% | 5.63% | +20.2% | |
| MLND | MILLENDO THERAPEUTICS INC | $20,949,000 | +88.7% | 1,396,615 | 0.0% | 5.04% | +76.0% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $20,811,000 | +7.5% | 2,188,331 | 0.0% | 5.01% | +0.3% | |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $17,640,000 | +118.0% | 2,571,450 | +16.9% | 4.25% | +103.4% |
| SRRA | SIERRA ONCOLOGY INC | $13,872,000 | +29.5% | 8,112,121 | 0.0% | 3.34% | +20.8% | |
| APTX | APTINYX INC | $12,920,000 | -75.5% | 3,190,079 | 0.0% | 3.11% | -77.2% | |
| ITRM | ITERUM THERAPEUTICS PLC | $12,186,000 | +58.1% | 1,538,316 | 0.0% | 2.93% | +47.5% | |
| Buy | NABRIVA THERAPEUTICS PLC | $10,386,000 | +77.3% | 4,256,526 | +6.1% | 2.50% | +65.5% | |
| ETTX | ENTASIS THERAPEUTICS HLDGS I | $9,119,000 | +66.0% | 1,349,953 | 0.0% | 2.20% | +54.8% | |
| SYBX | SYNLOGIC INC | $6,568,000 | +8.3% | 865,407 | 0.0% | 1.58% | +1.0% | |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $6,565,000 | +11.3% | 370,081 | +48.0% | 1.58% | +3.8% |
| BLCM | BELLICUM PHARMACEUTICALS INC | $3,543,000 | +15.4% | 1,051,441 | 0.0% | 0.85% | +7.7% | |
| CDTX | CIDARA THERAPEUTICS INC | $3,477,000 | +12.7% | 1,312,258 | 0.0% | 0.84% | +5.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.